Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report

BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90–95 % of mutations are either BRAF(V600E) or BRAF(V600K). Specific BRAF inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadevall, David, Vidal, Joana, Gallardo, Fernando, Zuccarino, Flavio, Arumí-Uría, Montserrat, Dalmases, Alba, Bellosillo, Beatriz, Montagut, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890269/
https://www.ncbi.nlm.nih.gov/pubmed/27255157
http://dx.doi.org/10.1186/s13256-016-0953-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890269/
https://www.ncbi.nlm.nih.gov/pubmed/27255157
http://dx.doi.org/10.1186/s13256-016-0953-0

Ejemplares similares